Primary Job Title Executive Chairman Primary Organization 
Albireo Pharma
Location Guernsey, Europe Regions Europe, Middle East, and Africa (EMEA) Gender Male
LinkedIn View on LinkedIn
After a career as a research scientist in both the UK and the US and nine years working in scientific management at Amersham International, David co-founded Cambridge Antibody Technology (CAT) in 1990. David was responsible for operational management from 1990 to 2002 and was CEO from 1996 to 2002. CAT listed on the London Stock exchange in April
1997 and Nasdaq in June 2001 raising over £120m on the public markets. Since leaving CAT in March 2002 David has been focusing on the development of early stage biotechnology companies including positions as non-executive chairman of Sosei Ltd, Arrow Therapeutics Ltd and Daniolabs Ltd, and director of Arakis Ltd. David is currently executive chairman of Nabriva Therapeutics and an advisor to Nomura Phase4 ventures. David was previously chairman of the UK’s BioIndustry association (BIA) and remains on their board. In 2006 he was awarded the OBE by HM Queen for services to the biotechnology industry.
